The Deal
Thursday, November 26, 
12:58 am

— CV Therapeutics —

Top tags

You have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "CV Therapeutics." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.

Community

Editor's Note

Editor's letter: Nov. 16, 2009

By Robert Teitelman

Beneath the veneer of Wall Streeters beats the same heart, stirred by the same determinants of behavior.


Regulatory

Of politics and pay

By Arthur F. Woodard

How to fix executive compensation rules without breaking the companies.


Industry Insight

Before the honeymoon ends

By Frank Aquila and Kathy Byran

Thinking differently about conflict resolution.


Judgment Call

The price of R&D

By Terri Garland and Mark Maxson

FAS 141(R): A new source of shareholder litigation against innovation-driven companies?


•  Community Home
•  The Deal On Facebook

Entries tagged "CV Therapeutics"

Little pharma blues

As the economy foundered, drug industry insiders looked forward to an M&A frenzy. But with a few exceptions, deals occurred only at the top of the food chain.


Cooley warms up to Gilead

Gilead tapped Cooley Godward's Rick Climan for advice on its $1.4B CV Therapeutics deal.


Latham leads the charge for CVT

Latham's Alan Mendelson is advising CVT as it fields Astellas' $1 billion offer.


Business as usual

Despite Lehman's bankruptcy and sale, most of its middle-market auctions grind on.



footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.